<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Clinical research Dermatologic and Ophthalmic Drugs Advisory Committee ISTA Pharmaceuticals Center for Drug Evaluation and Research Sodium hyaluronate Food and Drug Administration Health Pharmaceutical sciences |
Add to Reading List |
SESSION 1: NDA[removed]Bepotastine Besilate Ophthalmic Solution, 1 | FDA Advisory Committee Docket No. FDA–2011–N–0805DocID: Gwop - View Document |
| Anti-Inflammatory Drugs for Post-operative Indications Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) February 27, 2012 Renata Albrecht, MDDocID: FEmx - View Document |
| Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Date:DocID: Bmp9 - View Document |
| NAMFCU PRESS RELEASE ISTA PHARMACEUTICALS, INC. PAYS $15 MILLION IN SETTLEMENT OF OFF-LABEL MARKETING CLAIMS NAMFCU announced on July 17, 2013 that the states and the federal government reached an agreement with ISTA PhaDocID: zU5X - View Document |
| WHITEHOUSE-CONF-AGING.inddDocID: vUls - View Document |